Alphatec reports Q3 2026 results and cuts full‑year revenue outlook
Alphatec Holdings posted third‑quarter 2026 revenue of about $221 million, up roughly 13% year‑over‑year, with surgical revenue of $202 million rising 14%. The quarter saw case volumes increase 20% and new surgeon users grow 25%, while adjusted EBITDA reached $38 million (about 17% of revenue) and free cash flow turned positive at $6 million. The company lowered its full‑year 2026 revenue guidance to $862 million and now targets an adjusted EBITDA margin of roughly 16% for the year.
Why it matters
The reduced revenue outlook signals weaker top‑line growth than previously expected, which may pressure the stock price. Management’s focus on a 16% adjusted EBITDA margin highlights an effort to improve profitability, giving investors a clearer view of future earnings potential.
Key facts
- 1Q3 2026 total revenue was $221 million, up 13% year‑over‑year. stocktitan.net
- 2Surgical revenue was $202 million, up 14% year‑over‑year. stocktitan.net
- 3Case volumes grew 20% and net‑new surgeon users increased 25% in the quarter. orthospinenews.com
- 4Adjusted EBITDA was $38 million, representing 17% of revenue. orthospinenews.com
- 5Free cash flow for the quarter was $6 million. orthospinenews.com
- 6The company now expects full‑year 2026 revenue of $862 million. orthospinenews.com
Open questions
- Margin target differs: material 7 cites a 17% adjusted EBITDA margin, while material 9 cites a 16% target.
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.